Overview YF476 in Barrett's Esophagus Status: Completed Trial end date: 2017-12-27 Target enrollment: Participant gender: Summary A phase 2, randomised, double-blind, out-patient trial to determine if YF476 is a safe and effective treatment in patients with Barrett's esophagus. Phase: Phase 2 Details Lead Sponsor: Trio Medicines Ltd.Collaborators: Columbia UniversityUniversity of CambridgeTreatments: Gastrins